Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis
Brief Summary: The aim of the study is to establish whether treatment of superficial vein thrombosis (SVT) with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein thrombosis and pulmonary embolism), whether efficacy of low-molecular-weight heparin differs with regard to the dosage used (prevention, treatment), and to recognize groups of patients in which treatment with heparin is most efficient, as well as to determine factors that influence the efficacy of SVT treatment with heparin.


Options:
A: Inclusion Criteria:

* Patients with confirmed upper or lower extremity superficial thrombophlebitis by ultrasound imaging

Exclusion Criteria:

* Active, clinically significant bleeding
* Known hypersensitivity to NSAIDS, heparin or derivatives
* Currently pregnant or \< 1 week post-partum
* Acquired bleeding diathesis
* Known inherited bleeding disorder
* Renal failure
* Extremes of weight
* unable to return for repeat diagnostic testing or follow-up visit
* Concurrent deep-vein thrombosis
B: Inclusion Criteria:

* written informed consent to participate in the study
* symptomatic thrombophlebitis of the great saphenous vein measuring at least 10 cm or the small saphenous vein measuring at least 10 cm or a collateral of the great saphenous vein measuring at least 10 cm (within 7 days from the onset of the disease)
* age 18 to 85 years
* body weight 65 to 85 kg

Exclusion Criteria:

* inability to objectively confirm the diagnosis
* excessive or insufficient body weight (more than 85 kg or less than 60 kg)
* history of previous thromboembolic complications (including previous thrombophlebitis, vein thrombosis and pulmonary embolism)
* contraindications for anticoagulant treatment
* active bleeding or high risk for bleeding contraindicating treatment with (LMWH)
* diseases requiring anticoagulant treatment
* proximal or distal deep vein thrombosis or pulmonary embolism (either symptomatic or incidentally found asymptomatic)
* thrombophlebitis of the great saphenous vein at a distance of less than 5 cm from the saphenofemoral junction or thrombophlebitis of small saphenous vein at a distance of less than 3 cm from the saphenopopliteal junction
* thrombophlebitis that might arise as a consequence of a previous intravenous access (infusion thrombophlebitis), sclerotherapy or surgical treatment of chronic vein insufficiency
* pregnancy, known malignant disease or chemotherapy
* immobility
* advanced stage of kidney failure (GF \< 30 mL/min/1.72 m2)
* significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \>\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN
C: Inclusion criteria:

* Acute symptomatic superficial thrombophlebitis of the lower limbs at least 5 cm long diagnosed by compression ultrasound.

Exclusion criteria:

* Superficial thrombophlebitis that is within 3 cm from the sapheno-femoral junction,
* deep vein thrombosis on ultrasound exam, deep vein thrombosis or pulmonary embolism within last 6 months, treatment for cancer during last 6 months,
* anticoagulant medication for more than 48 hours prior to inclusion,
* need for oral non-steroidal anti-inflammatory drugs during the study, significant bleeding event during past month,
* major surgery within last 3 months, low platelet count (below 100×109/L),
* kidney disease (Calculated creatinine clearance \< 30 mL/min), woman of child-bearing potential not using reliable contraceptive method
D: Inclusion Criteria:

* acute symptomatic supragenual superficial vein thrombosis of the leg
* at least one of the following major risk factor for VTE:
* age \> 65 years or
* male sex or
* history of DVT/PE/SVT or
* history of cancer or active cancer or
* autoimmune disease or
* SVT of a non-varicose vein
* thrombus extension of at least 5 cm
* proximal thrombus end with more than 3 cm distance to the saphenofemoral junction (SFJ)
* age \> 18 years
* written informed consent

Exclusion Criteria:

* other indication for therapeutic anticoagulation such as acute deep vein thrombosis, acute pulmonary embolism, atrial fibrillation with indication for anticoagulant therapy
* any PE or DVT within last 6 months before inclusion
* clinical signs of PE without objective exclusion (CT or VQ scan, angiography)
* SVT without signs of thrombotic/inflammatory activity (activity signs: diameter \> 4 mm, pain, redness, elevated local or systemic temperature)
* SVT after sclerotherapy
* Duration of symptoms \> 3 weeks
* pretreatment of more than 72 h with therapeutic dosages of oral or parenteral anticoagulants
* pretreatment of more than 5 days with subtherapeutic oral or parenteral anticoagulants
* indication for escalated antiplatelet therapy (monotherapy with aspirin \> 325 g/d and any dual antiplatelet therapy)
* SVT closer than 3 cm to saphenofemoral junction (SVJ)
* anticipated superficial vein surgery within 90 days
* anticipated thrombolytic therapy within 90 days
* manifest clinically relevant bleeding
* clinically relevant bleeding in the last 30 days before study inclusion
* major surgery within last 30 days before inclusion
* ophthalmic, spinal or cerebral surgery within last 90 days
* severe head trauma within last 90 days
* hemorrhagic stroke within last 12 months
* hereditary or acquired severe hemorrhagic diathesis
* gastrointestinal bleeding within last 90 days requiring endoscopy
* uncontrolled arterial hypertension (systolic \> 180 mm Hg, diastolic \> 110 mm Hg)
* acute endocarditis
* low platelet count (\< 100 x 109/l)
* Prothrombin time \< 50 %
* calculated creatinine clearance \< 30 ml/min
* significant liver disease such as acute hepatitis, chronic active hepatitis, cirrhosis
* life expectancy \< 3 months
* any contraindications listed for rivaroxaban or fondaparinux
* women of child bearing potential without safe contraception method
* pregnant or breastfeeding women
* participation in another trial with pharmacological intervention

Answer: B